The US Food and Drug Administration (FDA) has approved Olumiant (baricitinib) for patients aged 12 years and older with severe alopecia areata, expanding the treatment’s existing approval for adults with the condition.
Developed by Eli Lilly, the once-daily oral JAK inhibitor received the expanded approval based on findings from the BRAVE-AA-PEDS Phase 3 trial, which was specifically designed to evaluate adolescents with severe alopecia areata - Read More.
The US Food and Drug Administration (FDA) has approved Olumiant (baricitinib) for patients aged 12 years and older with severe alopecia areata, expanding the treatment’s...
Novartis has received traditional approval from the US Food and Drug Administration (FDA) for Fabhalta® (iptacopan) to slow kidney function decline in adults with primary...
Basel- April 2024- Roche announced that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumour resection f...
